DBVT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Based on the investor's beginner level, long-term strategy, and available capital, DBV Technologies SA (DBVT) is a good buy. The stock has strong positive catalysts from analyst ratings and the successful Phase 3 VITESSE trial, which de-risks its lead product. While technical indicators are neutral and the stock has recently declined, the long-term potential outweighs short-term fluctuations.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 47.438, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 21.541, with key support at 20.265 and resistance at 22.817.
Successful Phase 3 VITESSE trial results for the Viaskin peanut patch, showing strong treatment effects and high compliance.
Analysts have raised price targets significantly, with targets ranging from $40 to $51, reflecting confidence in the company's growth potential.
Potential BLA submission in 2026 with a straightforward regulatory path.
Cash infusion from warrant exercise, sufficient to fund the potential product launch.
Recent price decline of -3.19% in the regular market session and -0.18% pre-market.
No significant hedge fund or insider trading trends, indicating neutral sentiment from key stakeholders.
Lack of recent news coverage.
In Q3 2025, revenue increased by 158.77% YoY to $2,774,000, showing strong growth. Net income improved by 8.94% YoY to -$33,164,000, but EPS dropped by -25.00% YoY to -0.24. Gross margin remained stable at 100%. While the company is not yet profitable, revenue growth and narrowing losses are positive signs.
Analysts are highly optimistic, with multiple firms raising price targets significantly after the Phase 3 VITESSE trial results. Cantor Fitzgerald, H.C. Wainwright, Citizens, and Guggenheim all maintain Buy or Overweight ratings, citing confidence in the Viaskin peanut patch's potential and a clear regulatory path.
